tetanus immunoglobulin
Trade name: Bastet
Biologicalapproved
Approved
Oct 17, 1957
Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. It is used to prevent tetanus in those who have a wound that is at high risk, have not been fully vaccinated with tetanus toxoid, or have HIV/AIDS. It is used to treat tetanus along with antibiotics and muscle relaxants. It is given by injection into a muscle. Part of the dose is injected at the site of the wound. — Wikipedia
Clinical trial activity
4 trials · 9 clinical orgs · 1 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Mar 1, 2007 (NCT00437671)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Tetanus toxinANTAGONIST
tetX antagonist
Approval history
- approvedOct 17, 1957
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAnti-tetanus immunoglobulin ↗
- NCATSV4SWI4RF4J ↗
- ChEMBLCHEMBL1201582 ↗
Also known as
- baytet
- homo-tet
- human clostridium tetani immune globulin
- human clostridium tetani toxoid immune globulin
- humotet
- immu-tetanus
- liberim t
- tetabulin
- tetanus immune globulin
- tetanus immune globulin
- tetanus immune globulin
- tetanus immune globulin human
- tetanus immune globulin (human )
- tetanus immune globulin,human
- tetanus immune globulin, human
- tetanus immune human globulin
- tetanus immunoglobulin
- tetanus immunoglobulin
- tet imglob
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07149454 | Phase 1 | Aug 18, 2025 | China National Biotec Group Co., Ltd, Shaanxi University of Chinese Medicine |
| NCT06360250 | Early Phase 1 (Phase 1) | Apr 10, 2024 | Anning City First People's Hospital, Changchun BCHT Biotechnology Co., Yunnan University of Traditional Chinese Medicine |
| NCT05664750 | Phase 3 | Dec 31, 2022 | Guangzhou Trinomab Biotech Co., Ltd., Peking University |
| NCT00437671 | Phase 4 | Mar 1, 2007 | Grifols, Northwell Health |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anning City First People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Changchun BCHT Biotechnology Co. | For profit | 1 | 1 | 1 | 2024 |
| China National Biotec Group Co., Ltd | For profit | 1 | 1 | 1 | 2025 |
| Grifols | For profit | 1 | 1 | 1 | 2007 |
| Guangzhou Trinomab Biotech Co., Ltd. | Government | 1 | 1 | 1 | 2022 |
| Northwell Health | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Shaanxi University of Chinese Medicine | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Yunnan University of Traditional Chinese Medicine | Academic/Hospital | 1 | 0 | 1 | 2024 |
9 organizations
Page 1 / 1